Phase IIA, open-label study, of AGEN1884 in combination with pembrolizumab in subjects with stage IV NSCLC whose tumors have high PD-L1 expression (>50%) and no EGFR or ALK mutations

Type of Cancer

Phase

Division (Location)

Study ID

NCT#

Brief Description
Phase IIA, open-label study, of AGEN1884 in combination with pembrolizumab in subjects with stage IV NSCLC whose tumors have high PD-L1 expression (>50%) and no EGFR or ALK mutations

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.